Andere Kunden interessierten sich auch für
![Craftsmanship in Competitive Industry; Being a Record of the Workshops of the Guild of Handicraft, and Some Deductions From Their Twenty-one Years' Ex]( "Craftsmanship in Competitive Industry; Being a Record of the Workshops of the Guild of Handicraft, and Some Deductions From Their Twenty-one Years' Ex")
Craftsmanship in Competitive Industry; Being a Record of the Workshops of the Guild of Handicraft, and Some Deductions From Their Twenty-one Years' Ex36,99 €![The Pharmaceutical Industry and Dependency in the Third World]( "The Pharmaceutical Industry and Dependency in the Third World")
The Pharmaceutical Industry and Dependency in the Third World105,99 €![Regulation of the Pharmaceutical Industry]( "Regulation of the Pharmaceutical Industry")
Regulation of the Pharmaceutical Industry74,99 €![The Pharmaceutical Era; 12]( "The Pharmaceutical Era; 12")
The Pharmaceutical Era; 1243,99 €![The New Competitive Advantage]( "The New Competitive Advantage")
The New Competitive Advantage217,99 €![The Japanese Pharmaceutical Industry]( "The Japanese Pharmaceutical Industry")
The Japanese Pharmaceutical Industry211,99 €![Pharmaceutical Marketplace Reform: Is Competition the Right Prescription?: Hearing Before the Special Committee on Aging, United States Senate, One Hu]( "Pharmaceutical Marketplace Reform: Is Competition the Right Prescription?: Hearing Before the Special Committee on Aging, United States Senate, One Hu")
Pharmaceutical Marketplace Reform: Is Competition the Right Prescription?: Hearing Before the Special Committee on Aging, United States Senate, One Hu38,99 €
The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products - even though new technologies have increased both the cost and the medical attractiveness of those products. Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research. This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.